| Species Reactivity | Human |
| Clone | KY-0118 |
| Source/Isotype | Human IgG1 (KDEL,L234A/L235A/P329G) |
| Application | / |
| Specificity | Detects PD1、IL2v |
| Gene | PD1&IL2v |
| Other Names | PD1: PDCD1, PD1, CD279, SLEB2 IL2v: VASN, SLITL2, Vasorin |
| Gene ID | PD1: 6622 (Human) IL2v: 114990 (Human) |
| Background | PD1-IL2V fusion antibodies are innovative bifunctional molecules in the field of cancer immunotherapy that achieve a synergistic effect of“Immune brake release + immune activation” by fusing PD-1 antibodies with an IL-2 variant (IL2V) . The core mechanism is that PD-1 antibody targets tumor-infiltrating PD-1 + T cells, delivering IL2V precisely to the tumor microenvironment while blocking PD-1/PD-L1 inhibitory signals; IL2V is engineered (e.g. , to avoid IL-2RΑ binding) to preferentially activate the IL-2RΒΓ pathway, specifically enhancing the proliferation, killing activity, and memory formation of effector T cells (e.g. , CD8 + T cells) , at the same time, it reduces the activation of regulatory T cells (Treg) and reduces the risk of toxicity such as vascular leak syndrome. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | KY-0118 |
| Source/Isotype | Human IgG1 (KDEL,L234A/L235A/P329G) |
| Application | / |
| Specificity | Detects PD1、IL2v |
| Gene | PD1&IL2v |
| Other Names | PD1: PDCD1, PD1, CD279, SLEB2 IL2v: VASN, SLITL2, Vasorin |
| Gene ID | PD1: 6622 (Human) IL2v: 114990 (Human) |
| Background | PD1-IL2V fusion antibodies are innovative bifunctional molecules in the field of cancer immunotherapy that achieve a synergistic effect of“Immune brake release + immune activation” by fusing PD-1 antibodies with an IL-2 variant (IL2V) . The core mechanism is that PD-1 antibody targets tumor-infiltrating PD-1 + T cells, delivering IL2V precisely to the tumor microenvironment while blocking PD-1/PD-L1 inhibitory signals; IL2V is engineered (e.g. , to avoid IL-2RΑ binding) to preferentially activate the IL-2RΒΓ pathway, specifically enhancing the proliferation, killing activity, and memory formation of effector T cells (e.g. , CD8 + T cells) , at the same time, it reduces the activation of regulatory T cells (Treg) and reduces the risk of toxicity such as vascular leak syndrome. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
